Literature DB >> 20544935

Crimson carrier, a long-acting contrast agent for in vivo near-infrared imaging of injured and diseased muscle.

Suresh I Prajapati1, Carlo O Martinez, Jinu Abraham, Amanda T McCleish, Joel E Michalek, Linda M McManus, Brian P Rubin, Paula K Shireman, Charles Keller.   

Abstract

The near-infrared wavelengths (700-900 nm) are the most suitable optical window for light penetration and deep tissue imaging in small animals. Herein we report a near-infrared fluorescent contrast agent, crimson carrier, which acts as a blood pool contrast agent to detect and quantify injury and disease in live animals. After determining the excitation-emission spectra and pharmacokinetics, crimson carrier was injected into myoinjured mice to monitor their recovery. Crimson carrier was also used to image transgenic mice with spontaneous tumors. Crimson carrier has maximal excitation and emission wavelengths of 745 nm and 820 nm, respectively. Elimination occurs predominantly via urinary excretion. We demonstrate the utility of this contrast agent for serial imaging of traumatized muscle as well as muscle tumors. The unique long-acting pharmacokinetics and urinary excretion route characteristics make crimson carrier a contrast agent of choice for the visualization of tumors and injured muscle or other tissues in live animal studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544935      PMCID: PMC2910161          DOI: 10.1002/mus.21682

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

Review 1.  Optical imaging: current applications and future directions.

Authors:  Gary D Luker; Kathryn E Luker
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

2.  Use of gene expression profiling to direct in vivo molecular imaging of lung cancer.

Authors:  Jan Grimm; David G Kirsch; Stephen D Windsor; Carla F Bender Kim; Philip M Santiago; Vasilis Ntziachristos; Tyler Jacks; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-23       Impact factor: 11.205

3.  Near-infrared imaging of injured tissue in living subjects using IR-820.

Authors:  Suresh I Prajapati; Carlo O Martinez; Ali N Bahadur; Isabel Q Wu; Wei Zheng; James D Lechleiter; Linda M McManus; Gary B Chisholm; Joel E Michalek; Paula K Shireman; Charles Keller
Journal:  Mol Imaging       Date:  2009 Jan-Feb       Impact factor: 4.488

Review 4.  Myotoxic phospholipases A2 and the regeneration of skeletal muscles.

Authors:  J B Harris
Journal:  Toxicon       Date:  2003-12-15       Impact factor: 3.033

5.  Delayed angiogenesis and VEGF production in CCR2-/- mice during impaired skeletal muscle regeneration.

Authors:  Oscar Ochoa; Dongxu Sun; Sara M Reyes-Reyna; Lindsay L Waite; Joel E Michalek; Linda M McManus; Paula K Shireman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-05-23       Impact factor: 3.619

6.  Biomarker system for studying muscle, stem cells, and cancer in vivo.

Authors:  Koichi Nishijo; Tohru Hosoyama; Christopher R R Bjornson; Beverly S Schaffer; Suresh I Prajapati; Ali N Bahadur; Mark S Hansen; Mary C Blandford; Amanda T McCleish; Brian P Rubin; Jonathan A Epstein; Thomas A Rando; Mario R Capecchi; Charles Keller
Journal:  FASEB J       Date:  2009-03-30       Impact factor: 5.191

7.  Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.

Authors:  Eri Taniguchi; Min Jung Cho; Benjamin R Arenkiel; Mark S Hansen; Omar J Rivera; Amanda T McCleish; Stephen J Qualman; Denis C Guttridge; Matthew P Scott; Mario R Capecchi; Charles Keller
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.